Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KMO | O15229 | 6/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285902 | 0.85 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1SMN1; SMN2KMOMMP13 | |
| SCHEMBL1671322 | 0.82 | KMO (0.50) | ALDH1A1SMN1; SMN2KMOMAPT | |
| SCHEMBL882676 | 0.80 | KMO (0.38) | ALDH1A1L3MBTL1SMN1; SMN2KMOMAPT | |
| SCHEMBL8148229 | 0.80 | SIRT6 (0.41) | L3MBTL1KMOHTT | |
| SCHEMBL24713180 | 0.80 | KMO (0.36) | ALDH1A1L3MBTL1SMN1; SMN2KMOMAPK1 | |
| SCHEMBL24184895 | 0.79 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1SMN1; SMN2KMOMMP13 | |
| Potassium Ion SCHEMBL4365217 | 0.78 | KMO (0.33) | ALDH1A1L3MBTL1KMOMAPK1ALOX15 | |
| SCHEMBL17132794 | 0.77 | KMO (0.50) | ALDH1A1SMN1; SMN2KMOMAPT | |
| SCHEMBL6884437 | 0.77 | BAZ2B (0.46) | ALDH1A1L3MBTL1SMN1; SMN2MAPK1ALOX15 | |
| SCHEMBL14872318 | 0.77 | CLK4 (0.35) | ALDH1A1L3MBTL1KMOMAPK1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167489-B1 | PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2013139822-A1 | NOVEL BISOXIME MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-26 | — | — | WO | disclosed |
| EP-2641901-A1 | Novel microbiocides | Syngenta Participations AG. (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | ALDH1A1 1154/4885L3MBTL1 1422/4885SMN1; SMN2 4778/4885 |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | ALDH1A1 1469/4885L3MBTL1 3677/4885SMN1; SMN2 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.